Harvard professor is surely very connected to both administration, regulation, technology and everything else.<p>It's literally impossible for an outsider to achieve this feat even if he has the initial money at his disposal.
<i>“I have an academic lifestyle. I’m not into ramen noodles, but my friends are academics, so it doesn’t really behoove me to be flashy,” Springer told Bloomberg at the time. “I feel that I’ve had more than enough wealth for myself for some time. I don’t feel I need more.”</i><p>Compare and contrast with:
<a href="https://youtu.be/eb3pmifEZ44" rel="nofollow">https://youtu.be/eb3pmifEZ44</a>
<a href="https://youtu.be/mOI8GWoMF4M" rel="nofollow">https://youtu.be/mOI8GWoMF4M</a>
<i>Less than two years later (of the IPO), and the 72-year-old (Timothy Springer) has ridden a 17,000% return in his Moderna shares — which he paid about $5 million for in the company’s early stages — into the billionaire club.</i><p><i>The Cambridge, Mass., biotech has jumped 162% this year, as of Wednesday’s close, surging on hopes for its mRNA-1273 coronavirus vaccine, one of the first (along with five other vaccines) to begin human trials.</i><p><a href="https://www.marketwatch.com/investing/stock/MRNA?countrycode=US" rel="nofollow">https://www.marketwatch.com/investing/stock/MRNA?countrycode...</a>